HDV was discovered in patients infected with hepatitis B virus (HBV). It generally makes ... 74% base pairing to form an unbranched rod-like structure. The genome sequence shows no homology ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve ...

Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...